DrStockPick.com Stock Report!
Friday July 24, 2009
Delta Petroleum Corporation (Nasdaq: DPTR); an independent oil and gas exploration and development company, today announced that it will host an investor conference call on Thursday, August 6, 2009 at 12:00 noon Eastern Time (10:00 am Mountain Time) to discuss operating results for the second quarter 2009.
NeurogesX, Inc. (Nasdaq: NGSX) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of the ongoing new drug application (NDA) review, the U.S. Food and Drug Administration (FDA) requested the study to determine whether an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program. The NDA for Qutenza in PHN has a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.
PowerSecure International, Inc. (Nasdaq: POWR) has scheduled its second quarter 2009 earnings release and conference call for Thursday, August 6, 2009, after the market close. The Company will issue its second quarter 2009 earnings release at approximately 4:15 p.m. eastern time, and will hold its earnings conference call from 5:30-6:30 p.m. eastern time.
American Vanguard Corporation (NYSE:AVD) announced today that its second quarter operating and financial performance has been negatively impacted by recent adverse agricultural industry trends. Delayed and reduced order placement from growers has caused many retail and distributor channels to embrace strict inventory control and adopt a “buy-only-as-needed” purchasing practice. This shrinkage of demand in the distribution inventory pipeline has been the most significant factor influencing American Vanguard’s second quarter sales volumes.
Cytori Therapeutics (NASDAQ:CYTX) has been informed that the United States Federal Court in the Central District of California upheld a June 2008 decision relating to U.S. patent number 6,777,231 (the ‘231 patent). The Court’s decision has no impact on Cytori’s products or clinical applications under development.
JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) announced today a further update of the status of its acquisition of CardioGenics Inc. by its Ontario, Canada subsidiary, CardioGenics ExchangeCo. Inc. The closing date for the acquisition, currently scheduled for a date on or before July 24, 2009, has been rescheduled to a date on or before July 31, 2009 to allow the parties sufficient time to attend to the final closing matters. All parties continue to dedicate their full resources to execute the remaining closing matters and anticipate that this will be the final adjournment necessary prior to the closing.
No comments :
Post a Comment